Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891284240> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2891284240 endingPage "e11989" @default.
- W2891284240 startingPage "e11989" @default.
- W2891284240 abstract "Current guidelines on the treatment of rheumatoid arthritis (RA) recommend early therapy targeting the achievement of low disease activity (LDA) or clinical remission. Little published information is available on the success of this treatment strategy in Latin America. In a subset analysis of patients from Latin America, we compared efficacy maintenance with etanercept 50 mg once weekly (ETN50) versus placebo (PBO), on a background of methotrexate (MTX) ± other non-biologic, disease-modifying antirheumatic drugs, in patients with moderate-to-severe RA who had achieved LDA with ETN50.In the Treat-to-Target trial, adult patients with active RA nonresponsive to MTX were treated with ETN50 for 24 weeks (Period 1). Patients achieving LDA were randomized to receive ETN50 or PBO for 28 additional weeks (Period 2). The proportion of patients maintaining LDA at week 52 and other efficacy and quality-of-life measures were assessed. Descriptive statistics are presented using last observation carried forward imputation of data.Of the 64 patients from Latin America treated in Period 1, 61 (95.3%) achieved LDA. Among patients receiving ETN50, 13/34 remained in LDA and 6/14 maintained remission at week 52 versus 6/27 and 4/10 patients receiving PBO. The median time to flare was 113 days and 33 days for the ETN50 and PBO groups, respectively. In the overall population, adverse events were reported in 37% and 43%, serious adverse events in 1% and 4%, and serious infections in 0% and 2% of patients in the ETN50 and PBO groups, respectively.In patients with RA from Latin America, continuing treatment with ETN50 after achieving LDA appears to result in a higher proportion of patients maintaining LDA and remission compared with switching to PBO. CLINICALTRIALS.NCT01578850." @default.
- W2891284240 created "2018-09-27" @default.
- W2891284240 creator A5014935848 @default.
- W2891284240 creator A5017946524 @default.
- W2891284240 creator A5024986694 @default.
- W2891284240 creator A5059248069 @default.
- W2891284240 creator A5065884210 @default.
- W2891284240 creator A5075732217 @default.
- W2891284240 creator A5091416598 @default.
- W2891284240 date "2018-09-01" @default.
- W2891284240 modified "2023-09-24" @default.
- W2891284240 title "Maintenance of low disease activity and remission with etanercept–disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis" @default.
- W2891284240 cites W1633595437 @default.
- W2891284240 cites W1879199789 @default.
- W2891284240 cites W2027004865 @default.
- W2891284240 cites W2052220931 @default.
- W2891284240 cites W2059107970 @default.
- W2891284240 cites W2068338283 @default.
- W2891284240 cites W2078110114 @default.
- W2891284240 cites W2081107208 @default.
- W2891284240 cites W2100274712 @default.
- W2891284240 cites W2114909821 @default.
- W2891284240 cites W2120426416 @default.
- W2891284240 cites W2142004396 @default.
- W2891284240 cites W2155007843 @default.
- W2891284240 cites W2416830647 @default.
- W2891284240 cites W2560833249 @default.
- W2891284240 cites W261957230 @default.
- W2891284240 cites W2622303856 @default.
- W2891284240 cites W58316457 @default.
- W2891284240 doi "https://doi.org/10.1097/md.0000000000011989" @default.
- W2891284240 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6133462" @default.
- W2891284240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30200078" @default.
- W2891284240 hasPublicationYear "2018" @default.
- W2891284240 type Work @default.
- W2891284240 sameAs 2891284240 @default.
- W2891284240 citedByCount "0" @default.
- W2891284240 crossrefType "journal-article" @default.
- W2891284240 hasAuthorship W2891284240A5014935848 @default.
- W2891284240 hasAuthorship W2891284240A5017946524 @default.
- W2891284240 hasAuthorship W2891284240A5024986694 @default.
- W2891284240 hasAuthorship W2891284240A5059248069 @default.
- W2891284240 hasAuthorship W2891284240A5065884210 @default.
- W2891284240 hasAuthorship W2891284240A5075732217 @default.
- W2891284240 hasAuthorship W2891284240A5091416598 @default.
- W2891284240 hasBestOaLocation W28912842401 @default.
- W2891284240 hasConcept C126322002 @default.
- W2891284240 hasConcept C141071460 @default.
- W2891284240 hasConcept C142724271 @default.
- W2891284240 hasConcept C197934379 @default.
- W2891284240 hasConcept C204787440 @default.
- W2891284240 hasConcept C27081682 @default.
- W2891284240 hasConcept C2776999253 @default.
- W2891284240 hasConcept C2777226972 @default.
- W2891284240 hasConcept C2777575956 @default.
- W2891284240 hasConcept C2781059491 @default.
- W2891284240 hasConcept C2908647359 @default.
- W2891284240 hasConcept C71924100 @default.
- W2891284240 hasConcept C99454951 @default.
- W2891284240 hasConceptScore W2891284240C126322002 @default.
- W2891284240 hasConceptScore W2891284240C141071460 @default.
- W2891284240 hasConceptScore W2891284240C142724271 @default.
- W2891284240 hasConceptScore W2891284240C197934379 @default.
- W2891284240 hasConceptScore W2891284240C204787440 @default.
- W2891284240 hasConceptScore W2891284240C27081682 @default.
- W2891284240 hasConceptScore W2891284240C2776999253 @default.
- W2891284240 hasConceptScore W2891284240C2777226972 @default.
- W2891284240 hasConceptScore W2891284240C2777575956 @default.
- W2891284240 hasConceptScore W2891284240C2781059491 @default.
- W2891284240 hasConceptScore W2891284240C2908647359 @default.
- W2891284240 hasConceptScore W2891284240C71924100 @default.
- W2891284240 hasConceptScore W2891284240C99454951 @default.
- W2891284240 hasIssue "36" @default.
- W2891284240 hasLocation W28912842401 @default.
- W2891284240 hasLocation W28912842402 @default.
- W2891284240 hasLocation W28912842403 @default.
- W2891284240 hasLocation W28912842404 @default.
- W2891284240 hasOpenAccess W2891284240 @default.
- W2891284240 hasPrimaryLocation W28912842401 @default.
- W2891284240 hasRelatedWork W1979251453 @default.
- W2891284240 hasRelatedWork W2110596704 @default.
- W2891284240 hasRelatedWork W2163339916 @default.
- W2891284240 hasRelatedWork W2352829214 @default.
- W2891284240 hasRelatedWork W2361407499 @default.
- W2891284240 hasRelatedWork W2372955595 @default.
- W2891284240 hasRelatedWork W2397817360 @default.
- W2891284240 hasRelatedWork W2414220780 @default.
- W2891284240 hasRelatedWork W2783466784 @default.
- W2891284240 hasRelatedWork W4235789707 @default.
- W2891284240 hasVolume "97" @default.
- W2891284240 isParatext "false" @default.
- W2891284240 isRetracted "false" @default.
- W2891284240 magId "2891284240" @default.
- W2891284240 workType "article" @default.